ႆᘙᎍƷ৑‫ޓ‬

SELECT BCヨ㦂䛻䛚䛡䜛HRQOL䛸་⒪⤒῭ホ౯ᢒ‫ޛ‬ᇕʍӸӞ‫ࠊދ‬ᇌ‫ܖٻ‬၏ᨈʐᐄ‫ٳ‬ᅹบᡀᨙኔ‫׎‬ᇌ၏ᨈೞನ˅ӨҔၲǻȳǿȸʐᐄ‫ٳ‬ᅹɦ‫଻ڸ‬ʚᢹ ᇌԡ᫾‫ܖٻ‬ဃԡᅹ‫ܖ‬ᢿဃԡҔᅹ‫ܖ‬ᅹ

䠄SELECT-BC䠖selection of effective chemotherapyfor breast cancer)ႉ‫ͤޥ‬‫׎‬ᇌ̬ͤҔၲᅹ‫ܖ‬ᨈҔၲȷᅦᅍǵȸȓǹᄂᆮᢿᅦဋ૟  ӷɥൗМή‫܇‬ଐஜᐮ࠿ᄂᆮૅੲȦȋȃȈɥ஭‫ٲ‬ᬐྸ ிʮ‫ܖٻ‬Ҕ‫ܖ‬ᢿ᧽‫ޓ‬၏ᨈᐮ࠿ᄂᆮૅੲǻȳǿȸ  ɶ‫ځ‬ሥྸȦȋȃȈဃཋወᚘȷȇȸǿሥྸ‫ܖ‬ᢿᧉ㐲ᒣ❳ஓ䚸Ώ㎶㝯⣖䚸ୗጔ᫭஧㑻䚸ⓑᒾ㻌೺䚸⚟⏣㻌ᩗ㻌ẟ฼ගᏊ䚸ୖᮧኤ㤶⌮䚸ᕝཎᣅஓ䚸ⴗཎᗣ༤䚸኱ᶫ㟹㞝ྥ஭༤ᩥ㻌䛣䛾⮫ᗋヨ㦂䛿බ┈㈈ᅋἲே䝟䝤䝸䝑䜽䝦䝹䝇䝸䝃䞊䝏䝉䞁䝍䞊䛜䚸኱㭉⸆ရᕤᴗᰴᘧ఍♫䛛䜙ዎ⣙䛻ᇶ䛵䛝㈨㔠ᥦ౪䜢ཷ䛡ᐇ᪋䛧䛯䜒䛾䛷䛒䜛䚹㻌߷Ҿਏʍிʮ‫ܖٻܖٻ‬ᨈҔ‫ܖ‬ኒᄂᆮᅹͤࡍᅹ‫ܖ‬ȷჃᜱ‫ݦܖ‬ૌဃཋወᚘ‫ܖ‬Ў᣼ᓬҾࡍҦிʮ‫ܖٻܖٻ‬ᨈҔ‫ܖ‬ኒᄂᆮᅹπσͤࡍҔ‫ݦܖ‬ૌ ဃཋወᚘ‫ܖ‬Ў᣼‫ٻ‬೛᩹ᨺɶ‫ܖ߻ྸܖٻځ‬ᢿʴ᧓ዮӳྸ߻‫ܖ‬ᅹဃཋወᚘ‫ܖ‬ӼʟҦ૨‫׎‬ᇌƕǜᄂᆮǻȳǿȸி၏ᨈʐᐄȷᏽၨϋᅹ12Ꮡ୎ίᾁὸᾉᚾ᬴ἙἈỶὅᴾ

Ꮡᴾ ୎ίᾀὸᴾ
¾ ᠃ᆆὉϐႆʐၶỉ඙ၲႸ೅ỊẆဃ‫܍‬஖᧓ỉࡨᧈấợỎᴾᵯᵭᵪỉોծỂẝỦẇᴾ¾ ᵐᵎᵏᵑ࠰ộỂỉʐၶᚮၲỾỶἛἻỶὅỂỊẆϐႆᵏഏ҄‫ܖ‬ၲඥểẲềỴὅἋἻἇỶἁἼὅộẺỊἑỿἇὅửԃớ඙ၲầࢍẪਖ਼‫ڜ‬ẰủẺầẆи˺ဇởᵯᵭᵪửᎋॾẲềỉਖ਼‫ڜ‬ỂỊễẟẇᴾ¾ ἑỿἇὅỂỊẆ஛ఴᅕኺᨦܹὉᏮൗễỄỉи˺ဇầᐮ࠿ɥբ᫆ểễẾềỦẇᴾ¾ ᠃ᆆὉϐႆʐၶỆấẟềẆᵱᵋᵏễỄỉኺӝ৴ầỮдầଐࠝᚮၲỂỊ̅ဇẰủềẟỦờỉỉẆᵱᵋᵏểἑỿἇὅửൔ᠋ẲẺᇹḫႻᚾ᬴ỊễẟẺỜẆஜᚾ᬴ίᵱᵣᵪᵣᵡᵲᴾᵠᵡὸầᚘဒẰủẺẇᴾ¾ ஜᚾ᬴ỉኽௐẆϐႆᾀഏ҄‫ܖ‬ၲඥểẲềẆμဃ‫܍‬஖᧓ỆấẬỦᵱᵋᵏỉἑỿἇὅỆ‫ݣ‬ẴỦ᩼эࣱầᚰଢẰủẺẇᴾ
䠄Lancet Oncology䛻ᥖ㍕䠅

ᵦᵣᵰᵐᨏࣱᴾ
᠃ᆆʐၶᴾ᠃ᆆʐၶỆ‫ݣ‬ẴỦᴾ҄‫ܖ‬ၲඥഭễẲᴾίᵏᶑᶒᴾ ᶊᶇᶌᶃὸᴾᵐᶌᶂᴾ

ᵑᶐᶂᴾᴾ‫ف‬फộẺỊஇ˯ᵔἅὊἋộỂጮụᡉẴᴾ

ᵰᴾᴾᴾᴾᴾᵱᵋᵏ፭ᴾᵑᶐᶂᴾᴾᵐᶌᶂᵋᶊᶇᶌᶃᴾ඙ၲỊ১ᛐẰủềẟỦ೅แἾἊἳὅểẲẺᴾᵢᵤᵧᵘᴾᵢᶇᶑᶃᵿᶑᶃᴾᶄᶐᶃᶃᴾᶇᶌᶒᶃᶐᶔᵿᶊᴾ ச̅ဇỉἑỿἇὅẆỴὅἚἻἇỶἁἼὅẆᵲᵱᵋᵏᴾᵹἑỿἇὅ
ᵠᵱᵟᵘᴾᵠᶍᶂᶗᴾᶑᶓᶐᶄᵿᶁᶃᴾᵿᶐᶃᵿᴾ
4፭ỉỚᵻẆỽἬἉἑἥὅἥἠἾἽἥὅẆᵡᵫᵤẆỶἼἠἘỽὅᴾ3

Ꮡ୎ίᾃὸᾉμဃ‫܍‬஖᧓ίᵭᵱὸᴾ
(This data was presented at ASCO2014)

Taxane(n=286)

S-1(n=306)

P

58.5 (21–75)

59.0 (29–75)

0.62䝩䝹䝰䞁ཷᐜయ≧ែ㻔㻑㻕㻌㻌㻌㻌㻌㻱㻾㻌䛚䜘䜃㻛䜎䛯䛿㻌㻼㼓㻾㻌㝧ᛶ㻌㻌㻌㻌㻌㻱㻾㻌䛚䜘䜃㻌㻼㼓㻾㻌㝜ᛶ㻌㻌㻌㻌㻌୙᫂㻌㻞㻝㻞㻌㻔㻣㻠㻚㻝㻕㻌
71 (24.8)
3 (1.0)㻞㻞㻟㻌㻔㻣㻞㻚㻥㻕㻌76 (24.8)
7 (2.3)㻴㻱㻾㻞㻌㼟㼠㼍㼠㼡㼟㻘㻌㼚㻌㻔㻑㻕㻌㝜ᛶ㻌୙᫂㻌

264 (92.3)
22 (7.7)282 (92.2)
24 (7.8)㻰㼕㼟㼑㼍㼟㼑㻌㼒㼞㼑㼑㻌㼕㼚㼠㼑㼞㼢㼍㼘㻘㻌㼚㻌㻔㻑㻕㻌䍸㻌㻞㻌ᖺ㻌㻞㻙㻡㻌ᖺ㻌䍹㻌㻡㻌ᖺ㻌୙᫂㻌㻺㼛㻌㼟㼡㼞㼓㼑㼞㼥㻌㻡㻣㻌㻔㻝㻥㻚㻥㻕㻌㻥㻤㻌㻔㻟㻠㻚㻟㻕㻌86 (30.1)
0 (0)45 (15.7)

㻢㻜㻌㻔㻝㻥㻚㻢㻕㻌㻝㻜㻟㻌㻔㻟㻟㻚㻣㻕㻌
94 (30.7)2 (1)47 (15.4)⫢㌿⛣㻘㻌㼚㻌㻔㻑㻕㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌䛒䜚㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌䛺䛧㻌96 (33.6)
190 (66.4)

103 (33.7)
203 (66.3)

0.98

㻌㻟㻥㻌㻔㻝㻟㻚㻢㻕㻌㻌㻞㻠㻣㻌㻔㻤㻢㻚㻠㻕㻌

35 (11.4)
271 (88.6)

0.42

㻌 䝍䜻䝃䞁⣔἞⒪Ṕ㻌㻘㻌㼚㻌㻔㻑㻕㻌 㻌㻌㻌㻌㻌㻌䛒䜚㻌㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌㻌㻌㻌㻌㻌㻌㻌㻌䛺䛧㻌80 (28.0)
206 (72.0)

80 (26.1)
226 (73.9)

㻌 䝩䝹䝰䞁⒪ἲ἞⒪Ṕ㻌㻘㻌㼚㻌㻔㻑㻕㻌 㻌 䛒䜚㻌㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 䛺䛧㻌

170 (59.4)
116 (40.6)

169 (55.2)
137 (44.8)

MedianOS

No.
eventsTaxane (n=286)

37.2 M

191

S-1 (n=306)

35.0 M

206

100
Overall survival (%)

0.50

0.95

ᴾᴾᴾᴾ

0.75

ᵱᵋᵏᴾ

80
60

ἑỿἇὅᴾ
ᴾᴾᴾᴾ

40

HR=1.05 (95% CI 0.86, 1.27)
p =0.015 (Non-inferiority margin:HR=1.33)

200⾡๓䞉⾡ᚋ⸆≀⒪ἲ㻌㻌 ⤒ཱྀ㻡㻙㻲㼁἞⒪Ṕ㻌㻘㻌㼚㻌㻔㻑㻕㻌㻌㻌㻌㻌㻌㻌㻌㻌䛒䜚㻌㻌 㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌㻌䛺䛧㻌ᴾἛἍἑỿἍἽᴾᵘᴾᵔᵎᵋᵕᵓᴾᶋᶅᵍᶋᵐᴾᵊᴾᵑᴾᶍᶐᴾᵒᡵ൑ῑᴾ ᴾ᩺දᴾᴾἣἁἼἑỿἍἽᴾᵘᵏᵕᵓᴾᶋᶅᵍᶋᵐᵊᴾᵑᴾᶍᶐᴾᵒᡵ൑ῑ᩺දᴾ
ᴾἣἁἼἑỿἍἽᴾᵘᵖᵎᵋᵏᵎᵎᴾᶋᶅᵍᶋᵐᵊᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾᴾ൑ᡵῑᵒᡵỆᵑ‫ׅ‬ῑ᩺දᴾᴾᴾᵱᵋᵏᵘᴾᵏଐᵐ‫ׅ‬ኺӝ৲ɨẆᶂᵿᶗᵏᵋᵐᵖẆᵔᡵ൑ᴾ‫ޖ‬К҄‫܇׆‬ᴾᴾ ˳ᘙ᩿ᆢᵆᵠᵱᵟᵇỆࣖẳềᴾᵐᶌᶂᴾ• ἭἽἴὅӖܾ˳ᴾᴾ Ὁᵠᵱᵟᵚᵏᵌᵐᵓᴾᶋᵐᾉᴾᵖᵎᴾᶋᶅᵍଐᴾ
ᵐᾉᵏᵎᵎᴾᶋᶅᵍଐᴾ
ᴾᴾὉᵏᵌᵐᵓṓᵠᵱᵟᾋᵏᵌᵓᴾᶋ• ᵢᵤᵧᴾᴾᴾὉᵠᵱᵟṔᵏᵌᵓᴾᶋᵐᾉᵏᵐᵎᴾᶋᶅᵍଐᴾ• ଀ᚨᴾ• Ꮑ᠃ᆆᴾ‫ف‬फộẺỊஇ˯ᵒἅὊἋộỂጮụᡉẴᴾ• ἑỿἇὅኒộẺỊᵓᵋᵤᵳ৲ɨഭᴾ

Ꮡ୎ίᾂὸᾉधᎍᴾ
ᖺ㱋୰ኸ್ (⠊ᅖ)ɼᙲᚸ̖᪮Ⴘᴾ ᴾɼμဃ‫܍‬஖᧓ίᵭᵱὸᴾ

ἑỿἇὅ፭ᴾ

Taxane
S-1

0.62
0.30
5Ꮡ୎ίᾄὸᾉஊܹʙᝋᴾ

0123456286306

240
258

1862081461355555

1513247(years)ᵭᵱỆấẟềᵱᵋᵏỉἑỿἇὅỆấẬỦ᩼эࣱầᚰଢẰủẺᴾ6ᚾ᬴ỉႸႎὉᚸ̖᪮Ⴘίᾀὸᴾ

(This data was presented at ASCO2014)

EventsNo. of patients
Fatigue
Alopecia
Edema
Sensory neuropathy
Arthralgia
Myalgia
Febrile neutropenia
Diarrhea
NauseaTaxane: n, (%)
Any
Grade
n =290153 (52.8)
12 (4.1)
220 (75.9)
ᴾ ᴾ ᴾ ᴾ111 (38.3)
12 (4.1)
143 (49.3)
9 (3.1)62 (21.4)
0 (0.0)64 (22.1)
1 (0.3)10 (3.4)
10 (3.4)
57 (19.7)
4 (1.4)66 (22.8)
3 (1.0) ᴾɼᙲᚸ̖᪮Ⴘᴾ•ᴾ μဃ‫܍‬஖᧓ᴾίᵭᶔᶃᶐᵿᶊᶊᴾᶑᶓᶐᶔᶇᶔᵿᶊᵘᴾᵭᵱὸᴾ ᴾиഏႎᚸ̖᪮Ⴘᴾᴾᴾᴾᴾ• ඙ၲ঺ы஖᧓ᴾᵆᵲᶇᶋᶃᴾᶒᶍᴾᶒᶐᶃᵿᶒᶋᶃᶌᶒᴾᶄᵿᶇᶊᶓᶐᶃᵘᴾᵲᵲᵤᵇᴾ• ໯‫ف‬फဃ‫܍‬஖᧓ᴾᵆᵮᶐᶍᶅᶐᶃᶑᶑᶇᶍᶌᴾ㘘ᶄᶐᶃᶃᴾᶑᶓᶐᶔᶇᶔᵿᶊᵘᴾᵮᵤᵱᵇᴾ• ஊܹʙᝋᴾᴾ• ͤࡍ᧙ᡲᵯᵭᵪᴾᵆᵦᵰᵯᵭᵪᵇᴾ
• ᝲဇ‫ݣ‬јௐίҔၲኺฎјௐὸᴾ

S-1: n, (%)
AnyGraden =307125 (40.7)
10 (3.3)
15 (4.9)
26 (8.5)
1 (0.3)29 (9.4)
1 (0.3)22 (7.2)
1 (0.3)33 (10.7)
0 (0.0)6 (2.0)6 (2.0)103 (33.6)
8 (2.6)100 (32.6)
4 (1.3)78ᚾ᬴ỉႸႎὉᚸ̖᪮Ⴘίᾁὸᴾ

ᵡᵭᵬᵱᵭᵰᵲᴾᶂᶇᵿᶅᶐᵿᶋᴾ

¾ͤࡍ᧙ᡲᵯᵭᵪᴾỊᴾᵣᵭᵰᵲᵡᴾᵯᵪᵯᵋᵡᵑᵎᵊᴾᵣᵯᵋᵓᵢᴾửဇẟẺẇᴾ¾҄‫ܖ‬ၲඥỆợỦ஛ఴᅕኺᨦܹᵆᵡᵧᵮᵬᵇᴾỊᴾᵮᵬᵯᴾᵆᵮᵿᶒᶇᶃᶌᶒᴾᵬᶃᶓᶐᶍᶒᶍᶖᶇᶁᶇᶒᶗᴾᵯᶓᶃᶑᶒᶇᶍᶌᶌᵿᶇᶐᶃᾉधᎍဇ஛ఴᅕኺᨦܹᴾᴾᴾᴾឋբᅚᵇửဇẟềᚸ̖ẲẺᵌᴾᴾFrom 258 institutions
Enrollment period: Oct 2006 - Jul 2010
Median follow up time: 34.6 months
Number of death events: 398

Patients enrolled䠄N=618)
Taxane (n=309)
S-1 (n=309)

Eligible䠄n=608䠅
gible䠄
䠄n=608䠅
Taxane (n=301)
1)S-1 (n=307)

ᴾᴾᴾᴾ

Survival analysis䠄n=592䠅
Taxane (n=286)
S-1 (n=306)
DTX (n=146)
PTX (n=140)¾ឋբᅚỉᚸ̖ỊẆ඙ၲЭẆ඙ၲ᧏‫ࢸڼ‬ᾂὈஉẆᾅὈஉẆᴾᴾᾀᾁὈஉỆᘍẾẺẇộẺẆᵣᵯᵋᵓᵢỉᚸ̖ỊӧᏡễᨂụᴾᴾᴾ
ᾅὈஉ൑ỆᘍẾẺẇᴾ

QOL analysis䠄n=391䠅
naaTaxane (n=179)
S-1 (n=212)
DTX (n=98)
PTX (n=81)

Ineligible䠄n=10䠅Ineligibl
lee
Taxane (n=8)
S-1 (n=2)
No treat
treatment䠄n=16䠅
atm
Taxane (n=15)
S-1 (n=1)

DTX: Docetaxel, PTX: Paclitaxel

910ᵯᵭᵪ‫ࡇݿ‬ỉᆔ᫏ᴾᵯᵭᵪửನ঺ẴỦᴾᙲእίἛἳỶὅὸᴾ11␁␗⏿⏋⏎␕‫ ׹‬ᴾͤᴾ ࡍ᧙ᡲ ᵯᵭᵪᵆᵦᵰᵯᵭᵪᵇᴾ

ᵟᵇ Ẑͤࡍཞ७ẑửย‫ܭ‬ẴỦἩἿἧỳỶἽ‫ࡇݿ׹‬ᴾ¾ ͤࡍὉᵯᵭᵪửನ঺ẴỦᙐૠỉᙲእỆếẟềẆẸủ
ẹủૠ᪮ႸẵếỉឋբẦỤನ঺ẰủềẟỦᴾ¾ ᐮ࠿ྵ‫ئ‬ဇᴾ¾ ᵣᵭᵰᵲᵡᴾᵯᵪᵯᵋᵡᵑᵎᴾ
ᴾᴾᴾᴾ
ᴾᵠᵇ Ẑͤࡍјဇẑửย‫ܭ‬ẴỦ̖͌˄Ậ‫ࡇݿ׹‬ᴾ¾ Ҕၲኺฎᚸ̖ỆဇẟỦẮểίᵯᵟᵪᵷᾉឋᛦૢဃ‫܍‬࠰ᵆᵯᶓᵿᶊᶇᶒᶗᴾᵟᶂᶈᶓᶑᶒᶃᶂᴾᵪᶇᶄᶃᴾᶗᶃᵿᶐᶑᵇỉᶏᶓᵿᶊᶇᶒᶗỆ̅ạὸửႸႎểẲề᧏ႆẰủẺᴾ¾ ᅈ˟ႎҔၲ᝻เᣐЎဇᴾ¾ ᵣᵯᵋᵓᵢᴾ

ᴾᴾᴾᴾἋἦἼἓἷỴἼἘỵểᅈ˟᩿ỉɟᢿửᨊẟẺờỉᴾ12䠄ୗጔ ᫭஧㑻ඛ⏕䜘䜚䛤ᥦ౪䠅ᵣᵭᵰᵲᵡᴾᵯᵪᵯᵋᵡᵑᵎỆợỦͤࡍ᧙ᡲᵯᵭᵪᚸ̖ᴾᵣᵭᵰᵲᵡᴾᵯᵪᵯᵋᵡᵑᵎỆợỦͤࡍ᧙ᡲᵯᵭᵪᚸ̖ᴾᴾᵆᵭᶌᴾᶒᶐᶃᵿᶒᶋᶃᶌᶒᴾᵿᶌᵿᶊᶗᶑᶇᶑᵇᴾ

ᴾᵆᵭᶌᴾᶒᶐᶃᵿᶒᶋᶃᶌᶒᴾᵿᶌᵿᶊᶗᶑᶇᶑᵇᴾ

μᑍႎͤࡍᵯᵭᵪᴾೞᏡἛἳỶὅἋἅỴᴾ௙஦䜔ᬑẁࢫлೞᏡᴾᏡ 䛾άື

ᵱᵋᵏᴾ

ᴾᴾᴾᴾ

៲˳ೞᏡᴾ៲Ꮱ ධᾎ䜎䛯䛿╔᭰䛘䛺䛹ᵱᵋᵏᴾ

ἑỿἇὅᴾἑỿἇὅᴾᵱᵋᵏ፭ầἑỿἇὅ፭ểൔỔềஊॖỆᑣ‫ڤ‬ỂẝẾẺᴾ

13

ᵱᵋᵏᴾ

ᴾᴾᴾᴾ

ἑỿἇὅᴾࢫлấợỎ៲˳ೞᏡỆấẟềờᵱᵋᵏ፭ầἑỿἇὅ፭ỆΟẾẺᴾ
14ᵣᵭᵰᵲᵡᴾᵯᵪᵯᵋᵡᵑᵎỆợỦͤࡍ᧙ᡲᵯᵭᵪᚸ̖ᴾ

ᵣᵭᵰᵲᵡᴾᵯᵪᵯᵋᵡᵑᵎỆợỦͤࡍ᧙ᡲᵯᵭᵪᚸ̖ᴾ

ᴾᵆᵭᶌᴾᶒᶐᶃᵿᶒᶋᶃᶌᶒᴾᵿᶌᵿᶊᶗᶑᶇᶑᵇᴾ

ᴾᵆᵭᶌᴾᶒᶐᶃᵿᶒᶋᶃᶌᶒᴾᵿᶌᵿᶊᶗᶑᶇᶑᵇᴾ

ೞᏡἛἳỶὅἋἅỴᴾ
ᛐჷೞᏡᴾኺฎႎ‫׉‬ᩊᴾ

࣎ྸೞᏡᴾ

ᅈ˟ೞᏡᴾᏡ

ᴾᴾᴾᴾ

ᐙ᪘䞉཭ே䛸䛾䛴䛝䛒䛔

ᵱᵋᵏᴾ

ᵱᵋᵏᴾ

ᵱᵋᵏᴾ
ἑỿἇὅᴾೞᏡἛἳỶὅἋἅỴᴾ

ᴾᴾᴾᴾ

ἑỿἇὅᴾ

ἑỿἇὅᴾ

ἑỿἇὅᴾ
ᵱᵋᵏᴾᛐჷấợỎ࣎ྸೞᏡỆấẟềờᵱᵋᵏ፭ầἑỿἇὅ፭ỆΟẾẺᴾ
15ኺฎႎ‫׉‬ᩊấợỎᅈ˟ೞᏡỆấẟềờᴾᵱᵋᵏ፭ầἑỿἇὅ፭ỆΟẾẺᴾ16ᾋᵮᵬᵯίधᎍဇ஛ఴᅕኺᨦܹឋբᅚὸᾍᴾᵣᵭᵰᵲᵡᴾᵯᵪᵯᵋᵡᵑᵎỆợỦͤࡍ᧙ᡲᵯᵭᵪᚸ̖ᴾ҄‫ܖ‬ၲඥỆợỦ஛ఴᅕኺᨦܹίᵡᵧᵮᵬὸᴾᴾ

ᴾᵆᵭᶌᴾᶒᶐᶃᵿᶒᶋᶃᶌᶒᴾᵿᶌᵿᶊᶗᶑᶇᶑᵇᴾೞᏡἛἳỶὅἋἅỴᴾ၊ᴾ ၘᴾஇ᭗ἂἾὊἛỉлӳӳᴾἂἾὊἛᾂˌɥỉႆဃྙᴾMaximum PNQ -Sensory grade(On treatment analysis)

Cumulative probability ofPNQ-Sensory grade3

Grade 0

1

23 4
ἑỿἇὅᴾ

ᴾᴾᴾᴾ

ᴾᴾᴾᴾ
ᵱᵋᵏᴾ

ἑỿἇὅᴾ

ᵱᵋᵏᴾ

၊ၘỆấẟềờᵱᵋᵏ፭ầἑỿἇὅ፭ỆΟẾẺᴾ17҄‫ܖ‬ၲඥỆợỦ஛ఴᅕኺᨦܹίᵡᵧᵮᵬὸỊᵱᵋᵏ፭Ểᴾ᫁ࡇấợỎἂἾὊἛầ˯ẟͼӼỆẝẾẺᴾᵣᵯᵋᵓᵢί̖͌˄Ậ‫ࡇݿ׹‬ὸỆợỦͤࡍ᧙ᡲᵯᵭᵪᚸ̖ᴾ

18Ⴚ੗Ҕၲᝲỉൔ᠋ᴾᵏὈஉίᵒᡵὸẝẺụỉᝲဇᴾ་⒪⤒῭ホ౯䛻⏝䛔䜛䛣䛸┠ⓗ䛸䛧䛶㛤Ⓨ㻌䠄෇䠅ᵱᵋᵏᴾ¥140,000¥120,000ᴾ¥40,000ࢸႆԼࢸࢸࢸࢸ

¥60,000ᴾ¥80,000

ᴾᴾᴾᴾέႆԼԼέέέԼ

¥100,000

ἑỿἇὅᴾᴾᴾᴾᴾέ ࢸႆ ႆԼᴾ Լᴾ¥20,000¥0ᵣᵯᵋᵓᵢἋἅỴỆấẟềờᵱᵋᵏ፭ầἑỿἇὅ፭ỆΟẾẺᴾ 19ἛἍἑỿἍἽᴾ

έႆԼᴾᵏᵏᵑᵊᵗᵑᵎ

ἣἁἼἑỿἍἽᴾᵑᡵ൑ᴾ
ᵏᵎᵗᵊᵑᵕᵎ

ࢸႆԼᴾ

ᵕᵒᵔᵒᵎ

ᵓᵔᵐᵖᵎ

ἣἁἼἑỿἍἽᴾ൑ᡵᴾᵏᵑᵕᵊᵐᵓᵎ
ᵕᵑᵕᵏᵎ

ᵱᵋᵏ
ᵔᵖᵊᵏᵓᵎ

ࢸႆԼỉ‫ئ‬ӳỊɲ፭Ệ‫ٻ‬ẨễࠀỊễẲᴾ20

Ⴚ੗᩼ҔၲᝲὉ᧓੗ᝲỉൔ᠋ᴾ
䠄෇䠅ኽௐỉộểỜᴾ὿῍ᵔὈஉỉӳᚘ᣿᫇ᴾ¥400,000¥350,000¥300,000

ἑỿἇὅᴾ¥250,000

ᵱᵋᵏᴾᵱᵋᵏ፭ỊẆ᠃ᆆὉϐႆʐၶỆ‫ݣ‬ẴỦɟഏ҄‫ܖ‬ၲ¥200,000¥150,000ඥểẲềẆμဃ‫܍‬஖᧓Ểἑỿἇὅ፭ỆэỤễẟ
ᴾᴾᴾᴾ

ᴾᴾᴾᴾ

¥100,000ẻẬỂễẪẆͤࡍ᧙ᡲᵯᵭᵪấợỎҔၲኺฎỂờ¥50,000¥0і΁੷ ᘺ៲φ‫ڂ‬ίʼя ᝲίỸỶἕἂễ
ᎍὸᴾỄὸᴾἑỿἇὅᴾ ᵏᵕᵑᵓᵓ ᵏᵖᵑᵏᵓᵔ ᵔᵏᵖᵗᵕ ᵕᵓᵔᵗᵔᵱᵋᵏᵓᵖᵑᵓ ᵏᵖᵎᵐᵑᵗ ᵏᵕᵖᵐᵏ ᵑᵐᵑᵒᵎʩᡫᝲᴾі΁੷‫ڂ‬ίधᎍὸᴾͳԼᝲᴾͤࡍ᫢Լᝲᴾܼ૎ۡ
ᝲᴾܼ‫ދ‬ોᡯᝲᴾӳᚘᴾӳᚘᴾᵒᵑᵗᵒᵕᵓᵔᵔᵑᵔᵔᵕᵑᵐᵒᵗᵓᵖᵎᵏᵔᵐᵓᵎᵏᵔᵑᵎᵑᵕᵗᵑᵑᵒᵐᵖᵓᵎᵎᵖἑỿἇὅ፭ỆΟụẆஊဇễ඙ၲᢠ৸ᏃỂẝỦẮểầᅆẰủẺẇᴾᵱᵋᵏ፭ỉ૾ầ‫̖ܤ‬ỂẝẾẺᴾ

21

22

ᜓᴾ ᠴᴾ ᵱᵣᵪᵣᵡᵲᴾᵠᵡᴾỆӋьẲềɦẰẾẺμềỉधᎍểẸỉܼଈỉ૾ẉᴾ
ᴾᴾᴾᴾ ᚾ᬴ỆӋьẲềɦẰẾẺᵐᵓᵖ଀ᚨỉᐮ࠿ᄂᆮᎍểἼắฌᎮỄạờẝụầểạắằẟộẲẺᴾἇὊἓἅὊἙỵ἟Ὂἑỉ૾ẉᴾ ᵡᵱᵮᵭᵰᚾ᬴ʙѦ‫ޅ‬ẆἙὊἑἍὅἑὊỉ૾ẉᴾắңщỄạờẝụầểạắằẟộẲẺẇᴾ23

24